Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01694277 · ClinicalTrials.gov registry record · Phase 3
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
A Phase 3 study, sponsored by AB Science.
- Completed
- Registry status
- Phase 3
- Development phase
- 258
- Enrollment target
NCT01694277 is a Phase 3 study that has completed, run by AB Science. The registered enrollment target is 258 participants.
The verdict
NCT01694277, a Phase 3 study, has completed, sponsored by AB Science.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 258 participants
- Enrollment target
Study Summary
The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in the treatment of patients with gastro-intestinal stromal tumor (GIST) after progression with imatinib.
Interventions
- DRUG Sunitinib
- DRUG Masitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2012-04 |
| Est. Completion | 2020-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01694277
The ClinicalTrials.gov registry entry for NCT01694277 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AB Science, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sunitinib is the first listed.
NCT01694277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01694277 about?
NCT01694277 is a clinical study titled "Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib". The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in the treatment of patients with gastro-intestinal stromal tumor (GIST) after progression with imatinib.
What is the current status of trial NCT01694277?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 258 participants. The study started on 2012-04. Estimated completion is 2020-12.
What interventions are being tested in trial NCT01694277?
The interventions under investigation include: Sunitinib (DRUG), Masitinib (DRUG).
Who is sponsoring clinical trial NCT01694277?
This trial is sponsored by AB Science, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.